Spotlight Therapeutics' cell|specific in vivo gene editing platform ...

Spotlight Therapeutics' cell-specific in vivo gene editing platform ...

Spotlight's TAGE enable cell-selective gene editing of undruggable targets in the TME without the need for viral or nanoparticle delivery.

New Page — Spotlight Therapeutics

Using cell-targeting proteins, for example, Spotlight potentially could deliver gene-editing enzymes into immune cells surrounding a tumor in an effort to treat ...

In vivo CRISPR gene editing - Spotlight Therapeutics

These gene editing therapeutics are designed to selectively bind, internalize and edit specific cells directly in situ.

Science — Spotlight Therapeutics

Spotlight's engineered RiboNucleoProtein (eRNP) platform is designed to unlock the full potential of in vivo gene editing therapies. ... cell-selective editing.

Spotlight Therapeutics

Spotlight therapeutics. In vivo gene editing. Illuminating life-changing therapeutics. Back to Top. Contact us. Spotlight Therapeutics 3980 Trust Way Hayward ...

Spotlight Therapeutics: making CRISPR deliver in vivo - Nature

The central idea is to target Cas endonuclease and its gRNA to specific cell types in vivo using a “library of parts” consisting of cell- ...

PR - Series B — Spotlight Therapeutics

Spotlight Therapeutics raises $36.5 million Series B to advance a pipeline of cell-targeted in vivo CRISPR gene editing biologics.

Spotlight Therapeutics - IPIRA-Berkeley

Developer of next-generation gene editing therapeutics in a preclinical pipeline. The company creates programmable nucleases that selectively target and edit ...

Company: Spotlight Therapeutics - CRISPR Medicine News

Spotlight is focused on developing first-in-class in vivo gene-editing therapeutics. To do this it uses its proprietary technology platform Targeted Active Gene ...

Startup unifies lab management to pave the way for Big Data analytics

Spotlight Therapeutics is pioneering cell-targeted in vivo CRISPR gene editing by creating a new class of programmable ribonuceloproteins called Targeted ...

Spotlight Therapeutics - Crunchbase Company Profile & Funding

Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body.

Spotlight Therapeutics Raises $36.5 Million Series B

Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, ...

Spotlight Therapeutics Company Profile: Overview and Full News ...

Spotlight Therapeutics' core focus lies in utilizing in vivo gene editing to create life-changing therapeutics. This cutting-edge approach allows them to target ...

CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting

The second approach is the direct delivery of a mixture of Cas9 mRNA and sgRNA into the cell, followed by their intracellular complexation to form RNPs. , The ...

Targeted active gene editing agent and methods of use

... edit nucleic acids within specific cell types in vivo and ex vivo. Further ... Spotlight Therapeutics Methods and compositions for nucleic acid-guided nuclease ...

Spotlight Therapeutics Appoints Visionary Global Pharma Drug ...

Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene ...

Spotlight Therapeutics - CB Insights

Spotlight Therapeutics is a biotechnology company focused on developing a new class of therapeutics through direct in vivo gene editing. The company's main ...

Spotlight Therapeutics - Valuation, Funding & Investors - PitchBook

Operator of a biotechnology platform intended to develop a new class of therapeutics by direct cell-targeted in vivo gene editing.

Spotlight raises $36.5M to advance non-viral gene editing tech, lead ...

Spotlight Therapeutics Inc., a company developing cell-targeted in vivo CRISPR gene editing biologics, has raised $36.5 million in series B ...

TAGE (Targeted Active Gene Editor) technology platform

Spotlight's proprietary technology platform develops programmable CRISPR ribonucleoproteins (RNPs) optimized for in vivo cell-targeted delivery. The modular ...